Business
Currency:USD
2024/Q3
Stock NameRevenueRatio
Cystic fibrosis franchise205.7M36.43%
Other products133.34M23.61%
Evrysdi56.75M10.05%
Trelegy37.59M6.66%
Tremfya37.29M6.60%
IMBRUVICA32.14M5.69%
Other royalty income and revenues31.52M5.58%
TYSABRI30.36M5.38%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States2.35B100.00%
